Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the CAR-T Therapy in Haematological Malignancy industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions along with the strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
Please note that the figures and tables shown in the sample are just for the purpose of demonstration, which may differ from those in the final report.
Competitive Landscape:
Celgene (Juno Therapeutics)
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad
Sorrento Therapeutics
Novartis
Aurora BioPharma
Pfizer
Mustang Bio
CARsgen Therapeutics
Gilead (Kite Pharma)
Autolus Therapeutics
Region:
-
China
-
North America
-
Europe
-
APAC
-
Latin America, Middle East and Africa
Type:
Allogeneic
Autologous
Application:
Hospitals
Cancer Research Centers
Others
Table of Content
Chapter 1 Industry Overview & Development Status in Global and China Market
-
1.1 CAR-T Therapy in Haematological Malignancy Industry Overview
-
1.1.1 CAR-T Therapy in Haematological Malignancy Market Scope and Market Segments
-
1.1.2 CAR-T Therapy in Haematological Malignancy Industry Characteristics
-
1.1.3 Global and China CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
1.1.4 Global and China CAR-T Therapy in Haematological Malignancy Production Value and Growth Rate (2017-2028)
-
1.2 Global CAR-T Therapy in Haematological Malignancy Market Size and Growth Rate by Type (2017-2028)
-
1.2.1 Allogeneic
-
1.2.2 Autologous
-
1.3 Global CAR-T Therapy in Haematological Malignancy Market Size and Growth Rate by Application (2017-2028)
-
1.3.1 Hospitals
-
1.3.2 Cancer Research Centers
-
1.3.3 Others
-
1.4 Market Analysis by Region
-
1.4.1 North America CAR-T Therapy in Haematological Malignancy Consumption Market Size and Growth Rate (2017-2028)
-
1.4.2 Europe CAR-T Therapy in Haematological Malignancy Consumption Market Size and Growth Rate (2017-2028)
-
1.4.3 APAC CAR-T Therapy in Haematological Malignancy Consumption Market Size and Growth Rate (2017-2028)
-
1.4.4 Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Consumption Market Size and Growth Rate (2017-2028)
-
1.5 Global CAR-T Therapy in Haematological Malignancy Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)
-
1.5.1 Global CAR-T Therapy in Haematological Malignancy Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)
-
1.6 China CAR-T Therapy in Haematological Malignancy Sales Volume, Price, Sales Value (2017-2028)
-
1.6.1 China CAR-T Therapy in Haematological Malignancy Sales Volume, Price, Sales Value (2017-2028)
Chapter 2 Global CAR-T Therapy in Haematological Malignancy Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Challenges and Restraints
-
2.1.2 Opportunities and Potentialities
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape
-
2.2.1 Market Concentration Rate Analysis
-
2.2.2 CAR-T Therapy in Haematological Malignancy Industry Porter's Five Forces Model Analysis
-
2.2.3 CAR-T Therapy in Haematological Malignancy Industry PEST Analysis
-
2.3 CAR-T Therapy in Haematological Malignancy Industry Chain Analysis
-
2.3.1 Raw Material Supplies
-
2.3.2 CAR-T Therapy in Haematological Malignancy Downstream Market Analysis
-
2.3.3 Upstream and Downstream Impacts on CAR-T Therapy in Haematological Malignancy Industry
Chapter 3 Global and China CAR-T Therapy in Haematological Malignancy Market, by Manufacturer
-
3.1 Global and China CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Market Share, by Manufacturer (2021&2022)
-
3.1.1 Global and China CAR-T Therapy in Haematological Malignancy Sales Volume, by Manufacturer (2021&2022)
-
3.1.2 Global and China CAR-T Therapy in Haematological Malignancy Sales Value, by Manufacturer (2021&2022)
-
3.1.3 Global and China CAR-T Therapy in Haematological Malignancy Market Share, by Manufacturer (2021&2022)
-
3.2 SWOT Analysis on Global and China CAR-T Therapy in Haematological Malignancy Market Top 3 Players
Chapter 4 Global and China CAR-T Therapy in Haematological Malignancy Market, by Type (2017-2028)
-
4.1 CAR-T Therapy in Haematological Malignancy Market Trend, by Type
-
4.2 Global CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value, Market Share and Price Trend, by Type
-
4.2.1 Global CAR-T Therapy in Haematological Malignancy Sales Volume and Market Share, by Type (2017-2028)
-
4.2.2 Global CAR-T Therapy in Haematological Malignancy Sales Value and Market Share, by Type (2017-2028)
-
4.2.3 Global CAR-T Therapy in Haematological Malignancy Price Trend, by Type (2017-2028)
-
4.3 China CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value, Market Share and Price Trend, by Type
-
4.3.1 China CAR-T Therapy in Haematological Malignancy Sales Volume and Market Share, by Type (2017-2028)
-
4.3.2 China CAR-T Therapy in Haematological Malignancy Sales Value and Market Share, by Type (2017-2028)
-
4.3.3 China CAR-T Therapy in Haematological Malignancy Price Trend, by Type (2017-2028)
Chapter 5 Global and China CAR-T Therapy in Haematological Malignancy Market, by Application (2017-2028)
-
5.1 Downstream Market Overview
-
5.2 Global CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Market Share, by Application
-
5.2.1 Global CAR-T Therapy in Haematological Malignancy Sales Volume and Market Share, by Application (2017-2028)
-
5.2.2 Global CAR-T Therapy in Haematological Malignancy Sales Value and Market Share, by Application (2017-2028)
-
5.3 China CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Market Share, by Application
-
5.3.1 China CAR-T Therapy in Haematological Malignancy Sales Volume and Market Share, by Application (2017-2028)
-
5.3.2 China CAR-T Therapy in Haematological Malignancy Sales Value and Market Share, by Application (2017-2028)
Chapter 6 Global CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export, by Region (2017-2022)
-
6.1 China CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
-
6.2 North America CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
-
6.3 Europe CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
-
6.4 APAC CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
-
6.5 Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
Chapter 7 North America CAR-T Therapy in Haematological Malignancy Market Analysis
-
7.1 North America CAR-T Therapy in Haematological Malignancy Market, by Type
-
7.2 North America CAR-T Therapy in Haematological Malignancy Market, by Application
-
7.3 North America CAR-T Therapy in Haematological Malignancy Market Analysis and Forecast, by Country
-
7.3.1 United States CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
7.3.2 Canada CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
7.3.3 Mexico CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 8 Europe CAR-T Therapy in Haematological Malignancy Market Analysis
-
8.1 Europe CAR-T Therapy in Haematological Malignancy Market, by Type
-
8.2 Europe CAR-T Therapy in Haematological Malignancy Market, by Application
-
8.3 Europe CAR-T Therapy in Haematological Malignancy Market Analysis and Forecast, by Country
-
8.3.1 Germany CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.2 UK CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.3 France CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.4 Italy CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.5 Nordic Countries CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.6 Spain CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.7 Belgium CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.8 Poland CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.9 Russia CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.10 Turkey CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 9 APAC CAR-T Therapy in Haematological Malignancy Market Analysis
-
9.1 APAC CAR-T Therapy in Haematological Malignancy Market, by Type
-
9.2 APAC CAR-T Therapy in Haematological Malignancy Market, by Application
-
9.3 APAC CAR-T Therapy in Haematological Malignancy Market Analysis and Forecast, by Country
-
9.3.1 China CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.2 Japan CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.3 Australia and New Zealand CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.4 India CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.5 ASEAN Countries CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.6 South Korea CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 10 Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Market Analysis
-
10.1 Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Market, by Type
-
10.2 Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Market, by Application
-
10.3 Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Market Analysis and Forecast, by Country
-
10.3.1 GCC Countries CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.2 Brazil CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.3 Nigeria CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.4 South Africa CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.5 Argentina CAR-T Therapy in Haematological Malignancy Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 11 Global and China CAR-T Therapy in Haematological Malignancy Company Profiles
-
11.1 Celgene (Juno Therapeutics)
-
11.1.1 Celgene (Juno Therapeutics) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.1.2 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.2 Bluebird Bio
-
11.2.1 Bluebird Bio Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.2.2 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.2.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.3 Collectis
-
11.3.1 Collectis Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.3.2 Collectis CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.3.3 Collectis CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.4 Allogene Therapeutics
-
11.4.1 Allogene Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.4.2 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.4.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.5 Celyad
-
11.5.1 Celyad Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.5.2 Celyad CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.5.3 Celyad CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.6 Sorrento Therapeutics
-
11.6.1 Sorrento Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.6.2 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.6.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.7 Novartis
-
11.7.1 Novartis Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.7.2 Novartis CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.7.3 Novartis CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.8 Aurora BioPharma
-
11.8.1 Aurora BioPharma Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.8.2 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.8.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.9 Pfizer
-
11.9.1 Pfizer Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.9.2 Pfizer CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.9.3 Pfizer CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.10 Mustang Bio
-
11.10.1 Mustang Bio Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.10.2 Mustang Bio CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.10.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.11 CARsgen Therapeutics
-
11.11.1 CARsgen Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.11.2 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.11.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.12 Gilead (Kite Pharma)
-
11.12.1 Gilead (Kite Pharma) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.12.2 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.12.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.13 Autolus Therapeutics
-
11.13.1 Autolus Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.13.2 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Profiles, Application and Specification
-
11.13.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
Chapter 12 CAR-T Therapy in Haematological Malignancy Industry Investment Prospect and Risk Assessment
-
12.1 CAR-T Therapy in Haematological Malignancy Industry Investment Prospect Assessment
-
12.1.1 Investment Opportunities in Segmented Markets
-
12.1.2 Investment Opportunities in Regional Markets
-
12.1.3 Investment Opportunities in Subdivided Industries
-
12.2 CAR-T Therapy in Haematological Malignancy Industry Investment Risk Assessment
-
12.2.1 Competitive Risk Analysis
-
12.2.2 Technology Risk Analysis
-
12.2.3 Policies and Enterprise System Risk Analysis
List of Tables and Figures
-
Figure Global CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Production Value and Growth Rate (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Production Value and Growth Rate (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Market Size and Growth Rate of Allogeneic (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Market Size and Growth Rate of Autologous (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Market Size and Growth Rate of Hospitals (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Market Size and Growth Rate of Cancer Research Centers (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Market Size and Growth Rate of Others (2017-2028)
-
Figure North America CAR-T Therapy in Haematological Malignancy Consumption Market Size and Growth Rate (2017-2028)
-
Figure Europe CAR-T Therapy in Haematological Malignancy Consumption Market Size and Growth Rate (2017-2028)
-
Figure APAC CAR-T Therapy in Haematological Malignancy Consumption Market Size and Growth Rate (2017-2028)
-
Figure Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Consumption Market Size and Growth Rate (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Sales Volume, Price, Sales Value (2017-2028)
-
Figure Porter's Five Forces Model Analysis
-
Figure Industry PEST Analysis
-
Table Global and China CAR-T Therapy in Haematological Malignancy Sales Volume, by Manufacturer (2021&2022)
-
Table Global and China CAR-T Therapy in Haematological Malignancy Sales Value, by Manufacturer (2021&2022)
-
Table Global and China CAR-T Therapy in Haematological Malignancy Market Share, by Manufacturer (2021&2022)
-
Figure Global and China CAR-T Therapy in Haematological Malignancy Market Share, by Manufacturer in 2021
-
Figure Global and China CAR-T Therapy in Haematological Malignancy Market Share, by Manufacturer in 2022
-
Table Global CAR-T Therapy in Haematological Malignancy Sales Volume, by Type (2017-2028)
-
Table Global CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Table Global CAR-T Therapy in Haematological Malignancy Sales Value, by Type (2017-2028)
-
Table Global CAR-T Therapy in Haematological Malignancy Sales Value Share, by Type (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Price Trend, by Type (2017-2028)
-
Table China CAR-T Therapy in Haematological Malignancy Sales Volume, by Type (2017-2028)
-
Table China CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Table China CAR-T Therapy in Haematological Malignancy Sales Value, by Type (2017-2028)
-
Table China CAR-T Therapy in Haematological Malignancy Sales Value Share, by Type (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Price Trend, by Type (2017-2028)
-
Table Global CAR-T Therapy in Haematological Malignancy Sales Volume, by Application (2017-2028)
-
Table Global CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Table Global CAR-T Therapy in Haematological Malignancy Sales Value, by Application (2017-2028)
-
Table Global CAR-T Therapy in Haematological Malignancy Sales Value Share, by Application (2017-2028)
-
Figure Global CAR-T Therapy in Haematological Malignancy Sales Value Share, by Application (2017-2028)
-
Table China CAR-T Therapy in Haematological Malignancy Sales Volume, by Application (2017-2028)
-
Table China CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Table China CAR-T Therapy in Haematological Malignancy Sales Value, by Application (2017-2028)
-
Table China CAR-T Therapy in Haematological Malignancy Sales Value Share, by Application (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Sales Value Share, by Application (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
-
Figure North America CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
-
Figure Europe CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
-
Figure APAC CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
-
Figure Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Production, Import, Consumption and Export (2017-2022)
-
Table North America CAR-T Therapy in Haematological Malignancy Sales Volume, by Type (2017-2028)
-
Table North America CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Figure North America CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Table North America CAR-T Therapy in Haematological Malignancy Sales Volume, by Application (2017-2028)
-
Table North America CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure North America CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure United States CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure United States CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Canada CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Canada CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Mexico CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Mexico CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Table Europe CAR-T Therapy in Haematological Malignancy Sales Volume, by Type (2017-2028)
-
Table Europe CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Figure Europe CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Table Europe CAR-T Therapy in Haematological Malignancy Sales Volume, by Application (2017-2028)
-
Table Europe CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure Europe CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure Germany CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Germany CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure UK CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure UK CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure France CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure France CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Italy CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Italy CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Nordic Countries CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Nordic Countries CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Spain CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Spain CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Belgium CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Belgium CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Poland CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Poland CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Russia CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Russia CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Turkey CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Turkey CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Table APAC CAR-T Therapy in Haematological Malignancy Sales Volume, by Type (2017-2028)
-
Table APAC CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Figure APAC CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Table APAC CAR-T Therapy in Haematological Malignancy Sales Volume, by Application (2017-2028)
-
Table APAC CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure APAC CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure China CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Japan CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Japan CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Australia and New Zealand CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Australia and New Zealand CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure India CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure India CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure ASEAN Countries CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure ASEAN Countries CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure South Korea CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure South Korea CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Table Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales Volume, by Type (2017-2028)
-
Table Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Figure Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Type (2017-2028)
-
Table Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales Volume, by Application (2017-2028)
-
Table Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure Latin America, Middle East and Africa CAR-T Therapy in Haematological Malignancy Sales Volume Share, by Application (2017-2028)
-
Figure GCC Countries CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure GCC Countries CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Brazil CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Brazil CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Nigeria CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Nigeria CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure South Africa CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure South Africa CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Figure Argentina CAR-T Therapy in Haematological Malignancy Sales Volume and Growth Rate (2017-2028)
-
Figure Argentina CAR-T Therapy in Haematological Malignancy Sales Value and Growth Rate (2017-2028)
-
Table Celgene (Juno Therapeutics) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Celgene (Juno Therapeutics) Product Profiles, Application and Specification
-
Table Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Bluebird Bio Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Bluebird Bio Product Profiles, Application and Specification
-
Table Bluebird Bio CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Collectis Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Collectis Product Profiles, Application and Specification
-
Table Collectis CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Allogene Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Allogene Therapeutics Product Profiles, Application and Specification
-
Table Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Celyad Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Celyad Product Profiles, Application and Specification
-
Table Celyad CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Sorrento Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Sorrento Therapeutics Product Profiles, Application and Specification
-
Table Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Novartis Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Novartis Product Profiles, Application and Specification
-
Table Novartis CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Aurora BioPharma Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Aurora BioPharma Product Profiles, Application and Specification
-
Table Aurora BioPharma CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Pfizer Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Pfizer Product Profiles, Application and Specification
-
Table Pfizer CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Mustang Bio Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Mustang Bio Product Profiles, Application and Specification
-
Table Mustang Bio CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table CARsgen Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table CARsgen Therapeutics Product Profiles, Application and Specification
-
Table CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Gilead (Kite Pharma) Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Gilead (Kite Pharma) Product Profiles, Application and Specification
-
Table Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Autolus Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Autolus Therapeutics Product Profiles, Application and Specification
-
Table Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
